Safety and efficacy of ketorolac in improving the prognosis of acute type A aortic dissection patients: a protocol of a randomized, double-blinded, and placebo-controlled study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

COVID-19* ; Aortic Dissection*/diagnostic imaging ; Aortic Dissection*/drug therapy ; Aortic Dissection*/surgery; Humans ; SARS-CoV-2 ; Ketorolac/adverse effects ; Prognosis ; Treatment Outcome ; Randomized Controlled Trials as Topic

Background: Acute type A aortic dissection (aTAAD) is a critical and life-threatening condition. Previous research has demonstrated that the use of ketorolac not only reduces the progression, incidence, and severity of aortic aneurysms in animal models, but also decreases postoperative mortality and complications in patients undergoing open abdominal aortic aneurysm replacement. However, there is a lack of studies investigating the efficacy of ketorolac in treating aTAAD in humans. Therefore, we conducted a study to evaluate the safety and efficacy of ketorolac in patients with aTAAD. Our hypothesis was that ketorolac treatment for aTAAD patients would meet safety indicators and effectively improve patient prognosis.
Methods/design: This study is a single-center, randomized, double-blinded, and placebo-controlled study. A total of 120 patients with aTAAD will be recruited and will be randomized into the ketorolac group and placebo group with a ratio of 1:1. Ketorolac tromethamine 60 mg per 2 ml will be intramuscularly injected within 2 h before surgery, followed by intramuscular injections of 30 mg per 1 ml BID. on the first and second postoperative days in the Ketorolac group, while 0.9% saline will be administered at the same dose, dosage form, and time in the placebo group. This study aims to evaluate the safety and efficacy of ketorolac in improving the prognosis of aTAAD. The primary endpoint is the composite endpoint event concerning drug-related adverse events. Secondary endpoints include drug-related adverse events, laboratory examination of blood, diagnostic imaging tests, clinical biomarkers, etc. DISCUSSION: This study has been approved by the Medical Ethics Committee of Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical College (approval number: 2023-197-02). This study is designed to evaluate the safety and efficacy of ketorolac in patients with aTAAD. All participating patients will sign an informed consent form, and the trial results will be published in international peer-reviewed journals.
Trial Registration: The Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) ChiCTR2300074394. Registered on 4 October 2023.
(© 2024. The Author(s).)

Arterioscler Thromb Vasc Biol. 2006 May;26(5):1137-43. (PMID: 16514081)
Vasc Health Risk Manag. 2005;1(2):149-53. (PMID: 17315401)
Circulation. 2020 Oct 6;142(14):1374-1388. (PMID: 33017217)
Crit Care. 2013 Feb 04;17(1):204. (PMID: 23394211)
Crit Care Nurse. 2019 Feb;39(1):15-25. (PMID: 30710033)
Circulation. 2022 Mar;145(9):659-674. (PMID: 35100526)
J Thorac Cardiovasc Surg. 2021 Sep;162(3):735-758.e2. (PMID: 34112502)
Vascular. 2021 Feb;29(1):15-26. (PMID: 32576118)
Ann Thorac Surg. 2021 Oct;112(4):1210-1216. (PMID: 33271116)
Circulation. 1999 Jul 6;100(1):48-54. (PMID: 10393680)
Cell Stem Cell. 2022 Jun 2;29(6):933-947.e6. (PMID: 35597234)
Eur J Cardiothorac Surg. 1995;9(5):242-6; discussion 247. (PMID: 7544988)
Ann Surg. 1990 Dec;212(6):705-13. (PMID: 2256762)
J Thorac Cardiovasc Surg. 2017 Sep;154(3):936-937. (PMID: 27239009)
Ann Thorac Surg. 2021 Apr;111(4):1111-1117. (PMID: 32980327)
Circulation. 2020 Jan 7;141(1):42-66. (PMID: 31887080)
J Am Coll Cardiol. 2020 Oct 6;76(14):1703-1713. (PMID: 33004136)
Eur J Cardiothorac Surg. 2016 Sep;50(3):567-73. (PMID: 27044900)
Ann Thorac Surg. 2002 Nov;74(5):S1885-7; discussion S1892-8. (PMID: 12440687)
Circulation. 2018 Apr 24;137(17):1846-1860. (PMID: 29685932)
Circulation. 2022 Dec 13;146(24):e334-e482. (PMID: 36322642)
Glob Heart. 2014 Mar;9(1):171-180.e10. (PMID: 25432126)
Eur Heart J. 2021 Nov 7;42(42):4373-4385. (PMID: 34534287)
J Thorac Cardiovasc Surg. 2005 Jan;129(1):112-22. (PMID: 15632832)
Iran J Vet Res. 2021 Summer;22(3):188-194. (PMID: 34777518)
Curr Cardiol Rep. 2022 Mar;24(3):209-216. (PMID: 35029783)
Ann Thorac Surg. 2022 Apr;113(4):1073-1092. (PMID: 35090687)
J Inflamm Res. 2022 Oct 10;15:5785-5799. (PMID: 36238764)

82241212 National Natural Science Foundation of China

Keywords: Ketorolac; Prognosis; Stanford type A aortic dissection

YZI5105V0L (Ketorolac)

Date Created: 20240410 Date Completed: 20240412 Latest Revision: 20240412

20240412

PMC11005260

10.1186/s13063-024-08093-x

38600561